Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1Abatacept, rituximab or tocilizumab
(D02994)		3件: Abatacept,
Rituximab,
Tocilizumab		3件: Tocilizumab ,
Rituximab (D02994),
Abatacept 💬		4件: CD80,
CD86,
IL6R,
MS4A1 💬		25件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Systemic lupus erythematosus, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Virion - Adenovirus 💬1件: 46 💬
2ABP 798 - Biosimilar to rituximab
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46 💬
3ABP 798 Biosimilar to Rituximab
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46 💬
4Administration of rituximab and methylprednisolone
(D02994)		2件: Methylprednisolone,
Rituximab		2件: Methylprednisolone ,
Rituximab (D02994) 💬		2件: MS4A1,
NR3C1 💬		2件: Hematopoietic cell lineage, Neuroactive ligand-receptor interaction 💬1件: 51 💬
5Alemtuzumab and Rituximab
(D02994)		2件: Alemtuzumab,
Rituximab		2件: Alemtuzumab ,
Rituximab (D02994) 💬		2件: CD52,
MS4A1 💬		1件: Hematopoietic cell lineage 💬1件: 60 💬
6Alemtuzumab, Rituximab
(D02994)		2件: Alemtuzumab,
Rituximab		2件: Alemtuzumab ,
Rituximab (D02994) 💬		2件: CD52,
MS4A1 💬		1件: Hematopoietic cell lineage 💬1件: 63 💬
7Belimumab in SLE patients / Rituximab in RA patients
(D02994)		2件: Belimumab,
Rituximab		2件: Rituximab (D02994),
Belimumab 💬		2件: MS4A1,
TNFSF13B 💬		5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬2件: 46, 49 💬
8Bendamustine, Rituximab
(D02994)		2件: Bendamustine,
Rituximab		2件: Rituximab (D02994),
Bendamustine 💬		1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 61 💬
9Combination of Protein A Immunoadsorption, Rituximab, Dexamethasone plus Azathioprine
(D02994)		3件: Azathioprine,
Dexamethasone,
Rituximab		3件: Azathioprine ,
Dexamethasone ,
Rituximab (D02994) 💬		2件: MS4A1,
NR3C1 💬		2件: Hematopoietic cell lineage, Neuroactive ligand-receptor interaction 💬1件: 35 💬
10Combination of Rituximab
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 63 💬
11Combination of Rituximab with subcutaneous belimumab
(D02994)		2件: Belimumab,
Rituximab		2件: Rituximab (D02994),
Belimumab 💬		2件: MS4A1,
TNFSF13B 💬		5件: Cytokine-cytokine receptor interaction, Hematopoietic cell lineage, Intestinal immune network for IgA production, NF-kappa B signaling pathway, Rheumatoid arthritis 💬1件: 63 💬
12Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 85 💬
13Cyclophosphamide/Rituximab
(D02994)		2件: Cyclophosphamide,
Rituximab		3件: Cyclophosphamide ,
Rituximab (D02994),
Cyclophosphamide 💬		1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13 💬
14Dexamethasone and Rituximab
(D02994)		2件: Dexamethasone,
Rituximab		2件: Dexamethasone ,
Rituximab (D02994) 💬		2件: MS4A1,
NR3C1 💬		2件: Hematopoietic cell lineage, Neuroactive ligand-receptor interaction 💬1件: 63 💬
15Double-Blind Rituximab
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 51 💬
16Dr. Reddy’s Rituximab (DRL_RI) 100mg
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46 💬
17Dr. Reddy’s Rituximab (DRL_RI) 500mg
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46 💬
18Eltrombopag combining rituximab
(D02994)		2件: Eltrombopag,
Rituximab		1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 63 💬
19Etanercepet, Rituximab, Abatacept, Tocilizumab, Sarilumab
(D02994)		4件: Abatacept,
Rituximab,
Sarilumab,
Tocilizumab		4件: Tocilizumab ,
Rituximab (D02994),
Abatacept ,
Sarilumab 💬		4件: CD80,
CD86,
IL6R,
MS4A1 💬		25件: Allograft rejection, Autoimmune thyroid disease, Cell adhesion molecules, Coronavirus disease - COVID-19, Cytokine-cytokine receptor interaction, EGFR tyrosine kinase inhibitor resistance, Graft-versus-host disease, HIF-1 signaling pathway, Hematopoietic cell lineage, Human cytomegalovirus infection, Intestinal immune network for IgA production, JAK-STAT signaling pathway, Kaposi sarcoma-associated herpesvirus infection, Non-alcoholic fatty liver disease, PI3K-Akt signaling pathway, Pathways in cancer, Rheumatoid arthritis, Systemic lupus erythematosus, Th17 cell differentiation, Toll-like receptor signaling pathway, Transcriptional misregulation in cancer, Type I diabetes mellitus, Viral myocarditis, Viral protein interaction with cytokine and cytokine receptor, Virion - Adenovirus 💬1件: 46 💬
20Experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab)
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 222 💬
21GP2013 - A Proposed biosimilar rituximab
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46 💬
22IDEC-C2B8 (rituximab)
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46 💬
23Immunosuppressive treatment (eg, rituximab)
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 64 💬
24Individualized dose of rituximab
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 49 💬
25Interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab
(D02994)		12件: Acetate,
Alemtuzumab,
Cladribine,
Dimethyl fumarate,
Fingolimod,
Glatiramer,
Natalizumab,
Ocrelizumab,
Ofatumumab,
Ponesimod,
Rituximab,
Teriflunomide		10件: Cladribine ,
Alemtuzumab ,
Rituximab (D02994),
Dimethyl fumarate ,
Ocrelizumab ,
Natalizumab ,
Ofatumumab ,
Fingolimod ,
Teriflunomide ,
Ponesimod 💬		7件: CD52,
DHODH,
ITGA4,
KEAP1,
MS4A1,
RRM1,
S1PR1 💬		30件: Arrhythmogenic right ventricular cardiomyopathy, Biosynthesis of cofactors, Cell adhesion molecules, Chemical carcinogenesis - reactive oxygen species, Dilated cardiomyopathy, Drug metabolism - other enzymes, ECM-receptor interaction, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Glutathione metabolism, Hematopoietic cell lineage, Hepatocellular carcinoma, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, Metabolic pathways, Neuroactive ligand-receptor interaction, Nucleotide metabolism, PI3K-Akt signaling pathway, Parkinson disease, Pathways in cancer, Purine metabolism, Pyrimidine metabolism, Regulation of actin cytoskeleton, Sphingolipid signaling pathway, Ubiquitin mediated proteolysis, Yersinia infection 💬1件: 13 💬
26Intravenous Rituximab
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 66 💬
27MabionCD20 (candidate biosimilar to rituximab)
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46 💬
28MabThera (Rituximab)
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬4件: 13, 46, 49, 53 💬
29Mabthera or biosimilar Rituximab
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 61 💬
30Mabthera or biosimilar rituximab product
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13 💬
31MabThera® (rituximab)
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46 💬
32Originator rituximab - Rituxan ® or MabThera ®
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46 💬
33Perfusion of treatment Rituximab
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13 💬
34Prednisone, low dose rituximab
(D02994)		2件: Prednisone,
Rituximab		2件: Prednisone ,
Rituximab (D02994) 💬		2件: MS4A1,
NR3C1 💬		2件: Hematopoietic cell lineage, Neuroactive ligand-receptor interaction 💬1件: 61 💬
35RhTPO in combination with Rituximab
(D02994)		2件: Recombinant Human Thrombopoietin,
Rituximab		1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 63 💬
36Rituxan (INN: Rituximab), brand name in the United States
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46 💬
37Rituxan (INN: Rituximab), brand name in the US
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46 💬
38Rituxan (rituximab)
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 49 💬
39Rituxan® (rituximab)
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46 💬
40RITUXIMAB
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬48件: 11, 13, 14, 19, 26, 35, 36, 40, 41, 42, 43, 44, 45, 46, 49, 50, 51, 52, 53, 55, 56, 60, 61, 63, 64, 65, 66, 83, 84, 85, 86, 93, 94, 96, 97, 162, 222, 229, 256, 271, 274, 283, 284, 285, 288, 296, 300, 331 💬
41Rituximab (anti-CD20)
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 53 💬
42Rituximab (Arm A)
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬2件: 43, 44 💬
43Rituximab (Arm B)
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬2件: 43, 44 💬
44Rituximab (EU)
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46 💬
45Rituximab (genetical recombination)
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 14 💬
46Rituximab (MABTHERA® or RITUXAN®).
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬2件: 35, 61 💬
47Rituximab (Mabthera®)
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 61 💬
48Rituximab (Rituxan)
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 11 💬
49Rituximab (RTX) and Azathioprine (AZA)
(D02994)		2件: Azathioprine,
Rituximab		2件: Azathioprine ,
Rituximab (D02994) 💬		1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 65 💬
50Rituximab (US)
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46 💬
51Rituximab - MabThera
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46 💬
52Rituximab 1g IV
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 162 💬
53Rituximab [MabThera/Rituxan]
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬2件: 46, 63 💬
54Rituximab [MabThera]
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46 💬
55Rituximab and Cyclophosphamide IV
(D02994)		2件: Cyclophosphamide,
Rituximab		3件: Cyclophosphamide ,
Rituximab (D02994),
Cyclophosphamide 💬		1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 35 💬
56Rituximab and Hyaluronidase Human
(D02994)		2件: Hyaluronidase,
Rituximab		4件: Rituximab (D02994),
Hyaluronidase ,
Hyaluronidase ,
Hyaluronidase 💬		1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 331 💬
57Rituximab combined with Omalizumab
(D02994)		2件: Omalizumab,
Rituximab		2件: Rituximab (D02994),
Omalizumab 💬		2件: FCER1A,
MS4A1 💬		5件: Asthma, Fc epsilon RI signaling pathway, Hematopoietic cell lineage, Phospholipase D signaling pathway, Sphingolipid signaling pathway 💬1件: 162 💬
58Rituximab combined with tacrolimus induction + rituximab maintenance
(D02994)		2件: Rituximab,
Tacrolimus		3件: Tacrolimus ,
Rituximab (D02994),
Tacrolimus 💬		6件: MS4A1,
PPP3CA,
PPP3CB,
PPP3CC,
PPP3R1,
PPP3R2 💬		34件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬1件: 222 💬
59Rituximab combined with tacrolimus induction + tacrolimus maintenance
(D02994)		2件: Rituximab,
Tacrolimus		3件: Tacrolimus ,
Rituximab (D02994),
Tacrolimus 💬		6件: MS4A1,
PPP3CA,
PPP3CB,
PPP3CC,
PPP3R1,
PPP3R2 💬		34件: Alzheimer disease, Amphetamine addiction, Amyotrophic lateral sclerosis, Axon guidance, B cell receptor signaling pathway, C-type lectin receptor signaling pathway, Calcium signaling pathway, Cellular senescence, Dopaminergic synapse, Glucagon signaling pathway, Glutamatergic synapse, Hematopoietic cell lineage, Human T-cell leukemia virus 1 infection, Human cytomegalovirus infection, Human immunodeficiency virus 1 infection, Kaposi sarcoma-associated herpesvirus infection, Lipid and atherosclerosis, Long-term potentiation, MAPK signaling pathway, Natural killer cell mediated cytotoxicity, Oocyte meiosis, Osteoclast differentiation, Oxytocin signaling pathway, PD-L1 expression and PD-1 checkpoint pathway in cancer, Pathways of neurodegeneration - multiple diseases, Prion disease, Renin secretion, T cell receptor signaling pathway, Th1 and Th2 cell differentiation, Th17 cell differentiation, Tuberculosis, VEGF signaling pathway, Wnt signaling pathway, cGMP-PKG signaling pathway 💬1件: 222 💬
60Rituximab Infusion
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬2件: 13, 222 💬
61Rituximab IT
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13 💬
62Rituximab IV
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13 💬
63Rituximab konsentrat til infusjonsvaeske oppløsning 10 mg/ml
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 13 💬
64Rituximab MabThera
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46 💬
65Rituximab, Cyclophosphamide, and Corticosteroids
(D02994)		2件: Cyclophosphamide,
Rituximab		3件: Cyclophosphamide ,
Rituximab (D02994),
Cyclophosphamide 💬		1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 222 💬
66Rituximab, Mabthera
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 53 💬
67Rituximab, MTX, folic acid
(D02994)		2件: Folic acid,
Rituximab		2件: Folic acid ,
Rituximab (D02994) 💬		1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46 💬
68Rituximab, observational study amon patients with active RA
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46 💬
69Rituximab-EU+ Rituximab-Pfizer x 2 Courses
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46 💬
70Rituximab-Pfizer
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46 💬
71Rituximab-Pfizer (PF-05280586) x 3 courses
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46 💬
72Rituximab-US + Rituximab-Pfizer x 2 Courses
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46 💬
73Rituximab/ Mabthera
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 271 💬
74SAIT101 (proposed rituximab biosimilar)
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46 💬
75SAIT101 (rituximab biosimilar)
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 46 💬
76Standard dose of rituximab
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 49 💬
77The Standard Steroid Treatment, Plasma Exchange and rituximab
(D02994)		1件: Rituximab1件: Rituximab (D02994) 💬1件: MS4A1 💬1件: Hematopoietic cell lineage 💬1件: 85 💬